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ScienceDirectThe successful introduction of antibody-based protein
therapeutics into the arsenal of treatments for patients has
within a few decades fostered intense innovation in the
production and engineering of antibodies. Reviewed here are
the methods currently used to produce antibodies along with
how our knowledge of the structural and functional
characterization of immunoglobulins has resulted in the
engineering of antibodies to produce protein therapeutics with
unique properties, both biological and biophysical, that are
leading to novel therapeutic approaches. Antibody engineering
includes the introduction of the antibody combining site
(variable regions) into a host of architectures including bi and
multi-specific formats that further impact the therapeutic
properties leading to further advantages and successes in
patient treatment.
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Introduction
Monoclonal antibodies (mAbs) and proteins derived in
part from mAbs have established themselves as one of the
largest groups of biologics (biotherapeutic proteins) that
are now being applied to a wide variety of therapeutic
applications [1]. The discovery and development of hy-
bridoma technology [2] created the foundation for mod-
ern day mAb discovery and development. This has been
augmented over the years by the application of phage [3]
and other display systems [4], transgenic animals [5], and
other approaches for mAb discovery. The successful
development of a therapeutic mAb often requires gener-
ation of a selective and potent molecule, humanization of
sequences, affinity maturation, Fc engineering to modu-
late effector functions, and engineering to deal withwww.sciencedirect.com biophysical liabilities that would negatively impact
manufacturability. In recent years, the production of
bispecific mAbs and Ab-derived therapeutics in a variety
of alternative formats are making their way into the clinic
[6]. Because of the vast number of publications on the
discovery, application, and engineering of mAbs, this
review will focus on updates of the generation of the
target, or antigen binding region, of the antibodies and
their incorporation into therapeutics.
Natural antibodies (Figure 1), or immunoglobulins, play
active roles in the immune system by recognizing and
defending against pathogens. The binding regions of the
mAb are made up of the heavy chain (HC) and light chain
(LC) variable domains that determine the specificity and
affinity of the antibody. The stem of the Y-shaped Ab is
called the Fc region, and it is composed of two pairs of
constant glycosylated HC domains. The Fc is responsible
for effector functions and contributes to the extended
half-life of the molecule in blood plasma. The Fc effector
functions include involvement in a number of cell-killing
mechanisms through its protein and carbohydrate inter-
actions with Fcg receptors and components of the com-
plement system [7] as well as agonism activity mediated
through crosslinking [8]. The Fc half-life functionality
is carried out mostly through interactions with the FcRn
[9].
Antibody variable (V)-regions of the Fab are one of the
focus areas of therapeutic engineering because of the
role they play in antigen or target binding [10]. The
antigen combining site is formed by the combination of
six hypervariable or complementarity-determining
regions (CDRs), three from both the HC and LC
(Figure 2). The amino acid residues of the V-regions
that are in direct contact with the antigen are referred to
as the paratope. The surface region of the antigen in
direct contact with the Ab paratope is referred to as the
epitope.
As the first structures of antibody Fab fragments became
available, it was discovered that of the six CDRs, all but
CDR-H3, have a limited number of main-chain confor-
mations, often referred to as canonical structures [11].
Recently, the early analyses have been expanded to
include the V-regions of all available antibodies and
antibody constructs [12,13]. This recent work has also
identified a small set of canonical structures for short
CDR H3 loops. This knowledge is being used to guide V-
region modeling/engineering studies, and is also being
used to detect residues in the CDRs that could influence
the biophysical properties (see Engineering for manufac-
turability section).Current Opinion in Structural Biology 2016, 38:163–173
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Structural model of a human IgG1. The Fab region is composed of the interaction between the variable and CH1 domains of the heavy and light
chains. The light chain is colored in green with the variable region colored in bright green. The heavy chain is colored brown with the corresponding
variable region colored in orange. The CH2 domain has glycosylation sites that orient between the two heavy chains in the Fc region.
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Representative arrangement of the complementarity determining regions (CDR) of the Fab region. The CDRs are composed of three respective
loops of the variable chains of the heavy and light chains. The six CDRs can interact with antigens to mediate the specificity and potency of an
antibody.
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Antibodies Chiu and Gilliland 165Described in the following sections are the methods used
to generate and engineer therapeutic antibodies. These
representative methods and how they relate to the thera-
peutic antibody discovery process are shown in
Figure 3. It should be realized that the development of
every therapeutic antibody follows a unique path that
incorporates many, but not all, of those described in the
sections below.
Animal immunization and hybridoma
generation
The field of therapeutic Abs began with the generation of
mAbs via the fusion of murine B cells and murine mye-
loma cells to produce single fusion cell lines (hybridomas)
which produce monoclonal Abs (mAbs) with a single
unique specificity [2]. In this way, mAbs against almost
any antigen are created, but the direct therapeutic use of
murine mAbs in humans is limited by both the high
incidence of harmful immune responses against the mu-
rine mAb and the lack of sufficient effector function for
murine mAbs. Today murine mAbs destined for thera-
peutics, after their generation by immunization of animals
(mice or rats), are then engineered to prevent an immuneFigure 3
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www.sciencedirect.com response in patients against non-human sequences. Ini-
tially this was partially achieved through chimerization,
replacement of the constant regions of the rodent Ab with
those of a human Ab [14]. Today V region humanization
often uses CDR grafting in which the CDRs are com-
bined with human V region framework sequences [15].
This process often reduces the mAb affinity, and hence, it
is usually followed by affinity maturation (see Affinity
Maturation section).
In order to eliminate the efforts required for humaniza-
tion of mAb therapeutics, transgenic mice and rat strains
have been developed to generate human mAbs directly.
In these animals, the murine immunoglobulin loci have
been replaced with human sequences. A number of
different approaches are now being used to generate
mAbs directly by using transgenic animals [5,16].
Microbial display
Because the antibody paratope is well understood, as
mentioned in the Introduction section, several
approaches have been developed to produce synthetic
combinatorial libraries for the identification of humand
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eutics. In a typical flow chart for the process of generating a
ad optimization. During hit and lead generation, the focus is being able
 binding arm sequences are changed to have a more human
nges in the Fab and Fc sequences are made to tune the functional
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166 New constructs and expression of proteinsmAbs for specific targets. This is especially useful in
developing mAbs against antigens that would be difficult
to obtain using animal based technologies, including
toxic, non-immunogenic, or self-antigens.
The display technology was originally described by Smith
in the form of phage display of peptides through their
incorporation as a fusion into the sequence of phage gene
III protein [17]. Modified versions of this phage display
approach are widely used as mAb discovery platforms.
Among the selection technologies currently available, the
display of antibody libraries on bacteriophage M13 by
genetic fusion of antibody fragments to the phage minor
coat protein pIII or its C-terminal domain is most fre-
quently used. The challenge is to link the DNA sequence
within the phage particle to the protein or peptide dis-
played on the surface of the phage particle. This linkage
facilitates the selection of the specific binding property.
Phage display is often used with Ab fragments that
include single chain variable region fragments and Fabs.
Screening involves the selection of molecules with the
desired properties including antigen binding, cross reac-
tivity in binding between defined species, increased
stability, etc. [18].
Alternatively, more focused approaches can vary the
sequences at specific positions in the CDR regions by
the wobbling gene synthesis. A variety of methods can be
used to screen the relevant residues [19] such as phage
display to generate human Abs directly from naı¨ve human
libraries [20]. The sequences have also been optimized
for expression in E. coli in a monovalent Fab format
thereby minimizing the potential of aggregation [21].
The intention of this work was to create a monovalent
Fab display that was optimal for the selection of high-
affinity antibodies, yet without losing antibodies with
medium affinity. It was shown that sufficient numbers
of Fab–pIII complexes are incorporated into the phage
particle to achieve this. The Fab format is stable and does
not form dimers or multimers, as is often the case for scFv
(a single chain version of the VH and VL domains of an
Ab). This format allows the selection for affinity and not
avidity and rapid off-rate screening in crude periplasmic
extracts. One drawback, however, is that they usually rely
on random combination and, thus most likely, unnatural
VH and VL antibody pairings.
Eukaryotic ribosome display
We extend upon the excellent reviews of synthetic Ab
technologies [22]. Poor expression and toxicity to the
host bacteria are often issues with Abs isolated from naive
libraries. Likewise tolerance of an antigen that is highly
homologous to host proteins will result in poor response in
getting antibodies. This problem can be bypassed by
using an in vitro protein evolution to create Abs that
can bind to a desired ligand. The libraries of DNA
sequences that code for Abs for selection can come fromCurrent Opinion in Structural Biology 2016, 38:163–173 synthetic Ab repertoire libraries [22], yeast display [23],
mammalian cell display [24], and in vitro vaccinia virus
display [25]. In these processes, each Ab sequence is
transcribed and translated in vitro. The DNA library
are typically fused to a spacer sequence lacking a stop
codon so as to prevent release factors from binding and
triggering the disassembly of the translational complex.
Thus the Ab can protrude out of the ribosome and fold
thus being a part of a complex of mRNA, ribosome, and
protein which can bind to the surface-bound ligand. The
complexes that bind well are immobilized and after
subsequent elution that allow for dissociation, the corre-
sponding mRNA can then be reverse transcribed back
into cDNA for identification. Repetition of this process
with greater selective pressure can be used to isolate even
better binders. Additional factors present in eukaryotic
ribosome display can enhance protein translation and
folding especially with a variety of post-translational
modifications better than the prokaryotic counterpart.
Ribosome display can select rare sequences and high-
affinity combining sites. Moreover with PCR, further
diversity can be introduced into the DNA pools after
selection to provide an efficient route for protein evolu-
tion. In addition, cell-free systems can be used to find
binders to toxic and proteolytically sensitive or unstable
proteins which can be intractable for selection using
microbial or animal methods. Nonetheless, these ribo-
some display screenings depend on the quality of the
antigen used for selection.
Single B cell
One drawback of the Ig transgenic murine systems is that
they cannot precisely imitate a human immune response
because of the effects of the murine genetic background
on antigen processing and B cell regulation. As a result,
the recovered antibodies might not display the precise
specificities of naturally occurring antibodies in humans.
Although this technique has produced numerous useful
Abs, its applicability is limited by differences in binding
properties between antibodies expressed in bacterial and
eukaryotic cells. In addition, phage display may result in
heavy-chain and light-chain combinations that do not
occur in the same B cell in vivo. As it is thought to be
important in antibody development to maintain the orig-
inal VH and VL pairing as exists in human B cells,
efficient strategies have been designed which are based
on the direct amplification of VH and VL region encoding
genes from single human B cells and their subsequent
expression in cell culture systems. It is possible to exploit
human immune reaction in the discovery of monoclonal
antibodies. Simply put, human immune response works
in the same way as that in a mouse or other non-human
mammal. Therefore, persons experiencing a challenge to
their immune system, such as an infectious disease,
cancer or a vaccination are a potential source of mono-
clonal antibodies directed at that challenge [26,27]. Hu-
man B cells have also been immortalized by electrofusionwww.sciencedirect.com
Antibodies Chiu and Gilliland 167or Epstein-Barr virus (EBV) transformation, with or with-
out the use of toll-like receptor ligands. However, these
techniques can be inefficient in some patients, such as
those with HIV infection, and transformed clones can be
lost because of instability.
Recently, cell-based microarray and microengraving tech-
niques are being applied to large populations of primary B
cells to facilitate the rapid screening and detection of
single cells secreting antibodies with the desired reactivi-
ty profiles [28,29].
The single B cell antibody approaches harbor the poten-
tial to isolate functional mAbs reactive against conforma-
tional determinants that are presented predominantly in
vivo and difficult to emulate in vitro. Because of the
strategy straightforwardness, the requirement of relative-
ly few cell numbers and the high efficiency in obtaining
specific mAbs in a rapid way are balanced by the
downsides: The need of adequate human donors and
the limitation to certain target molecules. B lymphocytes
expressing affinity matured Abs can be selected and
expanded [30,31]. Furthermore, valuable mAbs, have
been isolated from vaccinated [32] naturally immunized
donors [33] and patients with autoimmune disease [34].
Future advancements on microfluidic platforms, includ-
ing PCR cycling combined with next generation sequenc-
ing methods, are likely to exceed the current systems and
allow for high-throughput Ig gene sequence analyses of
individual antibody repertoires. By increasing the avail-
ability of such repertoires, single B cell antibody technol-
ogies are likely to take the lead in the development of
novel mAb therapeutics.
Affinity maturation
Abs generated either from phage, eukaryotic ribosome
display, or the transgenic route are often subjected to
further engineering that includes replacing residues with
liabilities in the binding region to improve its develop-
ability and ‘germ lining’ to replace unusual residues in the
framework residues with those present in the pre-mutat-
ed germ line genes to reduce the potential for immuno-
genicity. Immunogenicity can have multiple causes and is
influenced by: dose, route of delivery, presence of protein
aggregates, use of concomitant medication, dosing strat-
egy, genetic background as well as amino acid sequence.
In addition to reducing the non-human primary
sequences, there can be efforts to deimmunize protein
sequence by removing T cell epitopes identified either in
silico or using T cell stimulation assays [35]. When such
studies are necessary, they often lead to a reduction in
binding affinity and specificity. This is usually remedied
by an in vitro affinity maturation process [10,36].
Protein engineering can modulate the affinity of an Ab to
its Ag. This is relevant for Abs generated by phage displaywww.sciencedirect.com or using transgenic mice with human IgG as these tech-
nologies tend not to generate Abs with the same affinity as
immunization based techniques with wild-type animals.
Methods can be in 2 categories — display based methods
and structure based methods.
Display based methods rely on building libraries of var-
iants with changes that affect Ag interaction. Panning
under high stringency binding conditions can select for
improved affinity. Diversity can be introduced randomly
across the V gene or can be targeted to specific locations.
Because of the size limitations of library construction, it
can be difficult to randomize an entire binding site. Thus,
a mitigating approach is to focus on CDR-H3 that often
forms the majority of Ag contacts or to proceed sequen-
tially through the CDRs, optimizing one at a time and
then using the modulating sequences as the basis for
subsequent library generation [37].
Analysis of the antigen–antibody complex structures de-
posited in the PDB database had shown that the shape of
the antigen binding site differs for protein-, hapten-, and
peptide-binding antibodies and that the number and the
location of the antibody-antigen contact sites differ for
the various types of antigen [38]. Structure based meth-
ods rely on precise structural information of the Ab–Ag
interactions from structures or homology models from
which a small number of highly specific mutations in
the Ab binding site can be constructed [39]. Thus struc-
tural modeling can focus a more directed effort to opti-
mize antibody V-regions to deliver the desired potency
and selectivity.
Bispecific antibodies
Since most diseases involve several parallel signaling
pathways, multiple inhibitions of receptors and ligands
can cause better interferences of various ligand–receptor
signaling pathways; simultaneous targeting can limit the
development of disease cell resistance from single or
combination therapy. Polypharmacology to engage mul-
tiple targets simultaneously can improve the therapeutic
index of drug molecules so as to better treat a disease.
Although such effort using combination therapy has been
used in small-molecule drug discovery, this is being
expanded for therapeutic Abs [40]. There are advanta-
geous mechanisms of action that can be developed using
Abs that possess two binding specificities, bispecific anti-
bodies (BsAbs) [41]. An extensive effort to build plat-
forms for the redirection of immune cells to deliver
cytotoxicity of target cells can only be achieved by using
bispecific agents. The challenge is to identify a specific
set of Abs and determine the effective dose window to
generate the desired effect when targeting different
specificities. There are excellent reviews of the wide
range of protein engineering of bispecific Abs: Antibody
fragments without Fc domains; Antibody fragments with
Fc domains; Fc domains that can also be binders, and fullCurrent Opinion in Structural Biology 2016, 38:163–173
168 New constructs and expression of proteinsIgG BsAbs [42]. Alternatively, the BsAb platforms can
generate monovalent monospecific Abs to obtain more
specific biology [43,44].
One of the first applications of bispecific agents were T
cell redirection in which one Fv arm targeted CD3
domain in the T cell receptor complex and the other
Fv arm bound to an epitope on a target cell thereby
bringing cytotoxic T cells into proximity with a target cell
to promote lysis and elimination of the target cell. The
first sets of bispecific antibodies had several drawbacks:
they were difficult to generate large scale batches of
homogenous protein; their design were chimeric Abs that
resulted in having an undesirable immune response (hu-
man anti-drug Abs) decreased drug efficacy, safety, and
possibility of multiple administrations (Removab). The
second generation bispecific agents utilized antibody
fragments, such as a scFv, that were linked with peptide
linkers to create bispecific antibody-based molecules.
Introduction of a stability-engineered scFv as part of
an IgG-like BsAb enabled scalable production and puri-
fication of BsAbs, but such constructs required optimiza-
tion to produce the favorable biophysical properties
required for a successful therapeutic [45]. Thus, there
was a need to generate BsAbs without the need for
custom optimization of each fragment based design.
Recombinant bispecific antibody fragments without the
Fc domains have rapid in vivo clearance and require
optimization of protein engineering to generate large
scale amounts for manufacturability [46]. Although meth-
ods to increase half-lives such as PEGylation, N-glyco-
sylation, HSA or other carrier protein fusions are possible,
such fusions can introduce immunogenicity. Bispecific
agents can also be generated using scaffolds which may
not be based on Abs [6]. However the use of bispecific
agents using alternative scaffolds and Ab fusions has been
hindered in some cases by difficulties in the level of
purity coming from large-scale production of the con-
structs. These formats in some cases can have low solu-
bility, contain non-native linkers, lack stability, and have
rapid clearance in vivo.
Here, we focus on human IgG like bispecific Abs that
have been put together using several innovative technol-
ogies including knob in hole, strand exchange engineered
domain, chemical linked BsAbs, immunoglobulin domain
crossover, controlled Fab arm exchange, dual variable
domain. Having the BsAb in a format that is more like
a human Ab decreases the risk of generating a molecule
for a successful clinical profile [47].
MAbs can be selected and occasionally engineered to
have Fab arms with multiple specificities [48,49]. How-
ever, generating a Fab arm with this activity is still not yet
routine. Instead, it is preferable to have a platform that
can take a wide array of mAbs that could be processed to
generate a matrix of BsAbs. The variable regions ofCurrent Opinion in Structural Biology 2016, 38:163–173 different Abs can be concatenated to generate a dual
variable domain Ab [50]. However optimization of the
sequential order and the choice of linkers are required to
find the ideal candidate molecules. Alternatively, a native
BsAb can be obtained by conducting Ab selections using
either common light or heavy chain strategies [51]. Such
constructs can require a concerted selection scheme using
either display or transgenic animals to obtain human Abs
with such properties [5]. These forms of BsAbs can be
prepared by co-transfection of the genes of two parental
Abs that have Fc mutations that stabilize the heterodi-
mer: knobs and holes [52]; electrostatic steering [53];
immunoglobulin cross-over [54]; and strand exchange
engineered domain [55]. Because such constructs require
three or four cistron gene transfections, there can be
permutations of possible domain interactions. Thus,
there can be challenges to maximize the BsAb yields
during cell growth and from downstream purification. To
improve the separation of the desired BsAb from other
potential combinations of LC/HC pairings, different
BsAb engineering has been employed such as using
differential protein A binding [56], lambda/kappa light
chain [57] based affinity chromatography. An extensive
maturation process may have to be established for the
optimization of BsAb yield and stability [58].
To broaden the screening process of a wide array of mAbs
in a BsAb format, there are methods to generate BsAb
using purified parental mAbs with the respective CH3
domain point mutations [59,60]. This controlled Fab
arm exchange process is promising because of biophysi-
cal, activity, and pharmacokinetic similarity as well as
compatibility of manufacturability to human Ab [61]. In
addition, these BsAb technologies allow for incorporation
of Fc engineering to enhance the potential of therapeutic
efficacy.
Lead optimization
After identification of therapeutic Abs for different mech-
anisms of action such as neutralizing soluble mediators,
binding and killing of cells, and regulating cell function,
the Abs will require optimization of the affinity, selectiv-
ity, epitope engagement, Fc functionality for the target
biology efficacy. The Fab arms can be selected to modu-
late antigen specificity and binding affinity using affinity
maturation of the variable domain; humanization to de-
crease immunogenicity; engineering of the variable do-
main to lower the isoelectric point to lower elimination of
IgG [62,63].
In addition to the Fab arm activity, the Fc domain can be
modified to increase the therapeutic potency of the Abs.
The choice of the constant (Fc) region centers on whether
specific effector functions (stimulatory functions, tumor
cytotoxicity, pathogen phagocytosis, immune cell patho-
genicity, hypersensitivity, toxin/virus neutralization, B
cell activation) are required and the need for a suitablewww.sciencedirect.com
Antibodies Chiu and Gilliland 169in vivo half-life [64]. The choice of IgG1, IgG2 and IgG4
isotypes can affect engagement with Fc receptors that act
as activators, inhibitors and regulators of immunity
[8,65]. Each isotype has a different hinge and CH1
structure which can affect overall Ab activity. Likewise,
there are point mutations to the Fc domains that can
enhance or abrogate Fc receptor engagement [66]. Cell
depleting activity can also be mediated by complement
activation and ADCC through Fc engineering of IgG
hexamers assembled at the cell surface [67]. It is critical
to tune selection of the Fab and Fc domain activity since
there can be interactions between the Fab and Fc
domains with targets with different epitopic density
[68].
Pharmacokinetic modulation
IgG antibodies have a half-life that binds to the neonatal
receptor, FcRn, in a pH dependent manner which con-
tributes to their long half-life [69]. Fc engineering can
increase Ab half-life though stronger binding to FcRn
which could lead to less frequent dosing [70,71]. Likewise
there are mutations which can shorten the half-life [72].
Notwithstanding, there are other factors besides FcRn
binding such as overall charge of the variable region
which can affect pharmacokinetics [73].
Human heavy chain genes also exhibit extensive struc-
tural polymorphism(s) and, being closely linked, are
inherited as a haplotype. Polymorphisms (allotypes) with-
in the IgG isotype were originally discovered and de-
scribed using serological reagents derived from humans;
demonstrating that allotypic variants can be immunogen-
ic and provoke antibody responses as a result of allo-
immunization [74]. Different IgG1 allotypes have differ-
ent influence with FcRn binding which affect pharmaco-
kinetics [75]. Thus, if anti-therapeutic antibody
responses are encountered in chronic diseases when
patients are dosed on a continuing basis, the mechanism
of action should be determined if the cause is due to
variable region or allotype recognition.
Engineering for manufacturability
Although Abs from phage, hybridomas, or display tech-
nologies can be selected for affinity, potency, Fc func-
tionality, and biological activities, such lead molecules
can have poor biophysical properties that can result in
problematic developability issues such as poor expres-
sion, solubility, promiscuous cross-reactivity, and poor
pharmacokinetic profiles. Establishing early stage devel-
opability screening assays capable of predicting late stage
behavior is therefore of high value to minimize develop-
ment risks.
The complexity of an antibody mAb can be subject to
multiple mechanisms of degradation [76]. Therapeutic
antibodies need to possess the chemical and physical
stability to withstand degradation that can occur duringwww.sciencedirect.com the manufacturing process, packaging, storage, and deliv-
ery [77]. Poor stability can result from amino acid mod-
ifications such as deamidation, oxidation, isomerization,
cyclization, etc. [78], glycation [79,80], and Ab disulfide
shuffling [81]. The process to generate recombinant Abs
can result in aggregation, lack of solubility at concentra-
tions required for the therapeutic product profile, loss of
structural integrity due to fragmentation or clipping
[82,83] and chemical instability of the amino acid residues
[84]. Partial unfolding of the tertiary structure of Abs can
result in exposure of normally buried hydrophobic faces
that they can interact to result in aggregation [85]. While
Abs possess glycans attached to N297 of the CH2 domain
of the Fc, glycosylation of the variable regions is not
preferred because of variability of the therapeutic product
was well as potential interference on antigen binding [86].
Better understanding of the aforementioned heterogene-
ity of therapeutic molecules can permit development of
strategies to better identify the potential modifications to
mitigate the risks [87].
Different methods that include oxidation, glycation,
high and low pH holds have been introduced to charac-
terize the relationship between protein stability and
antibody structure [88]. Relative stability of therapeu-
tic antibody candidates can be evaluated primarily
through mAb response to thermal degradation, yet this
technique is not always predictive of stability in manu-
facture, shipping, and storage. Stress studies can be
conducted to select leads as well as guide sequence
optimization [77,88].
Computational tools can predict potential manufacturing
risks that can occur within the CDR regions through
analysis of the CDR interactions with framework residues
to permit more rational approaches for stability improve-
ment and for the elimination of hydrophobic patches that
can affect solubility [89,90,91]. If such mutagenesis
significantly affects activity, then protein formulation will
be required to maintain the Ab integrity [92,93]. Ideally,
in silico assessment of manufacturing risks of hits coming
from immunization, microbial display, eukaryotic ribo-
some display, and single B cell can help expedite the
therapeutic Ab discovery efforts by focusing efforts on
more viable leads.
For antibody therapeutics that rely on Fc-mediated ef-
fector function for their clinical activity, the terminal
sugars of Fc glycans have been shown to be critical for
safety or efficacy [94,95]. The production of Abs in
different hosts can alter the IgG1 Fc glycoforms and also
affect the chemical degradation profiles [96,97]. Howev-
er, differences in glycosylation coming from different cell
types is of less importance compared with process related
parameters such as cell growth conditions [98]. Different
glycosylation variants have also been shown to influence
the pharmacodynamic and pharmacokinetic behaviorCurrent Opinion in Structural Biology 2016, 38:163–173
170 New constructs and expression of proteinswhile other Fc glycan structural elements may be in-
volved in adverse immune reactions [99].
Conclusions and future directions
Since the arrival of the first therapeutic mAb in 1986,
there are more than 294 mAbs which are approved or
investigational drugs in the clinic (36 chimeric mAbs,
258 humanized mAbs). The large surface area of the
CDRs optimize the potential of obtaining the potency
and specificity to achieve clinical proof of concept target
activation, inhibition, of blocking of ligand interactions.
Most mAbs have targeted soluble and membrane pro-
teins, glycoproteins, glycolipids, and carbohydrates. Since
these targets may have dynamic structures, the selection
of the relevant mAb will require screening a wide array of
epitopes. To obtain mAb diversity, multiple approaches
to generate V regions may be required. Each screening
method has complementary advantages and disadvan-
tages to obtain diverse molecules. Upon discovery of
mAbs that target different epitopes, the next effort would
be to trigger different mechanisms of action using Fc
engineering. The properties of eliciting Fc effector func-
tion, control of pharmacokinetics and tissue specificity
can tune the mAb to different pathogenic disorders. To
increase the potential of differentiation with other mAbs,
increase of functionality and differentiation can be
obtained with combining different mAbs with distinct
properties into a bispecific format. In addition, there is
already great effort to link multispecificity using coupling
with small molecule drugs as well as other protein
domains to elicit new biological activity. Likewise the
coupling of Fab and Fc activity provides greater potential
for innovation. Concomitant to the process of mAb func-
tional activity optimization, it is critical to couple evalua-
tion of manufacturability to the discovery of the lead
molecule. Engineering stability, homogeneity by removal
of aggregation hotspots, and developability can minimize
chemistry, manufacturability, deviceability, and control
liabilities. The approaches that have been described will
continue to evolve leading to faster development of
therapeutics with better biological and biophysical prop-
erties that will address unmet patient needs.
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